Navigation Links
Population Health Impact Institute Invites Organizations To Serve as Test Sites for Methods Evaluation Process(TM) (MEP(TM)) Accreditation Program:
Date:12/3/2008

rs

Reserve your Webinar seat now at: https://www2.gotomeeting.com/register/933241803. Please invite your colleagues as well.

PHII is recruiting medical and disease management organizations and employers to serve as test sites to peer review the MEP Accreditation Program. Successful sites will have the option to become a PHII Accredited organization.

The MEP Certification Program will enable individuals to become recognized for understanding the MEP principles.

To learn more, see http://www.phiinstitute.org/ or call (513) 349-5846.

PHII's mission is to promote credible, transparent, standardized, and replicable impact evaluations of defined population health management programs for public and private sector organizations through education, research and benchmarking services.


'/>"/>
SOURCE The Population Health Impact Institute
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
2. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
3. Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
4. Planning for 2020: increasing elderly population poses huge challenges in cancer care
5. Migrating Tick Populations Pose Year-Round Disease Threat for People and Pets
6. Those With Disabilities as Well as Aging Population Throughout Country Now Have Access to Thousands of Specialized Products
7. Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase
8. Population Covered by Dental Benefits Increases
9. The widening mortality gap between people with rheumatoid arthritis and the general population
10. Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference
11. Study projects 60 percent increase in ESRD population by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 1DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 2Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 1Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 2Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 1Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 2